Hypertonic solutions for the treatment of diabetic patients in peritoneal dialysis

9^th International Conference on Dialysis and Renal Care

August 18-19, 2016 London, UK

Arduino Arduini

CoreQuest Sagl, Switzerland

Posters & Accepted Abstracts: J Nephrol Ther

Abstract :

Diabetes is the leading cause of kidney failure. To stay alive, most of kidney failure patients must go on dialysis. A significant proportion of diabetic kidney failure patients are treated with peritoneal dialysis (PD), an home-based therapy where the excess of fluid can only be removed by filling the peritoneal cavity with an hypertonic solution containing large amounts of glucose. The high glucose load along with insulin treatment, the only anti-diabetic therapeutic option available, result in survival rates much worse for diabetic kidney failure patients than for non-diabetic patients. Therefore, diabetic kidney failure is a condition with a significant unmet medical need. Our aim is to complete the development of proprietary anti-diabetic hypertonic PD solutions, containing different combinations of xylitol, L-carnitine and polydextrin. These innovative PD solutions will be characterized by osmotic strengths comparable to those commercially available, but with higher biocompatibility and able to ameliorate glycemic control in diabetic patients in PD therapy. Our hypertonic PD solutions are expected to improve dialysis efficiency and increase survival rates of diabetic patients in PD. In addition, insulin and non-insulin dependent diabetic kidney failure patients in PD may equally use our hypertonic solutions.

Biography :

Email: a.arduini@corequest.ch